Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Feb

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

A New Risk Model for Esophagectomy Draws on the STS National Database

Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA

Ultra–Low-Dose Immunotherapy in Relapsed or Refractory Solid Tumors

ASCO and Conexiant Launch ASCO AI in Oncology

Self-Acupressure May Ease Fatigue in Ovarian Cancer Survivors